Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Nhu CoSZSE:002001 -1.15%98 EBITDA Margin % is 37.95% as of Jun. 2026, which is 13% below its 10-year median of 43.52. GuruFocus rates SZSE:002001 with a GF Score™ of 98/100 and a GF Value™ of ¥28.59 (Fairly Valued). The stock has 3 warning signs investors should review. Among 960 Drug Manufacturers companies, Zhejiang Nhu Co ranks better than 91.15% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zhejiang Nhu Co's EBITDA for the
three
months ended in Jun. 2026 was ¥2,594 Mil. Zhejiang Nhu Co's Revenue for the
three
months ended in Jun. 2026 was ¥6,835 Mil. Therefore, Zhejiang Nhu Co's EBITDA margin for the quarter that ended in Jun. 2026 was 37.95%.
Zhejiang Nhu Co (SZSE:002001) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zhejiang Nhu Co EBITDA Margin % Related Terms
Zhejiang Nhu Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zhejiang Nhu Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Nhu Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Nhu Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Nhu Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Nhu Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Nhu Co (SZSE:002001) has a EBITDA Margin % of 37.95% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhejiang Nhu Co and its competitors. This is 13% below median its historical median of 43.52. Over the past decade, Zhejiang Nhu Co's EBITDA Margin % has ranged from 34.91 to 50.64. According to the industry distribution chart, Zhejiang Nhu Co ranks #85 out of 960 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Zhejiang Nhu Co's EBITDA Margin % too high?
Zhejiang Nhu Co's current EBITDA Margin % of 37.95% is 13% below median its 10-year median of 43.52. Over the past 10 years, this metric has ranged from a low of 34.91 to a high of 50.64. The Drug Manufacturers industry median EBITDA Margin % is 11.89. Zhejiang Nhu Co's value of 37.95% is 219.3% above this industry median. Based on the distribution chart, Zhejiang Nhu Co ranks #85 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Nhu Co has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Nhu Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Nhu Co ranks #85 out of 960 companies for EBITDA Margin %. This places Zhejiang Nhu Co in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 11.89. Zhejiang Nhu Co's value of 37.95% is 219.3% above this benchmark. Historically, Zhejiang Nhu Co's own EBITDA Margin % has ranged from 34.91 to 50.64 over the past decade. While the company's 10-year median is 43.52 vs. the industry median of 11.89, Zhejiang Nhu Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Nhu Co's current EBITDA Margin % of 37.95% is 219.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zhejiang Nhu Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Nhu Co's current EBITDA Margin % is 37.95%, which is 13% below median its own 10-year median of 43.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Nhu Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Nhu Co (SZSE:002001) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.59, compared to a current price of ¥26.55 — trading 7.1% below its estimated fair value. The current EBITDA Margin % is 37.95%, which is 13% below median its 10-year median of 43.52 and 219.3% above the Drug Manufacturers industry median of 11.89. Zhejiang Nhu Co's overall GF Score™ is 98/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zhejiang Nhu Co (SZSE:002001), the current EBITDA Margin % is 37.95% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Nhu Co (SZSE:002001) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Nhu Co stock appears to be undervalued.
The current stock price of ¥26.55 is trading 7.1% below its estimated GF Value™ of ¥28.59.
GuruFocus considers Zhejiang Nhu Co to be Fairly Valued.
Key valuation signals for SZSE:002001:
EBITDA Margin %: 37.95% (13% below median its 10-year median of 43.52)
GF Value™: ¥28.59 vs. price of ¥26.55 (7.1% below fair value)
Industry Position: 219.3% above the Drug Manufacturers median (#85 of 960)
No single metric tells the full story. See the SZSE:002001 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives, and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer, and Anti-bacterial, with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3, and coenzyme Q10, and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.
98GF Score
Get the complete analysis for SZSE:002001
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002001 has been successfully added to your 
